Abstract 1638P
Background
FOLFIRINOX and gemcitabine-nabpaclitaxel (GnP) are both standard first-line treatment regimens for advanced pancreatic ductal adenocarcinoma (PDAC), however, predictive biomarkers are currently lacking to guide treatment selection. We aimed to investigate the prognostic and predictive value of class III β-Tubulin (TUBB3) and human equilibrative nucleoside transporter 1 (hENT1) expression, which have previously been shown to be associated with taxane and gemcitabine resistance in advanced PDAC.
Methods
We conducted a retrospective analysis of 106 patients with advanced PDAC at Hacettepe University Cancer Institute. TUBB3 and hENT1 immunohistochemical staining were analyzed in tumor specimens and scored jointly according to the intensity of expression: high score (TUBB3low/hENT1high) and low score (TUBB3high/hENT1high, TUBB3low/hENT1low or TUBB3high/hENT1low). Response rates and progression-free survival (PFS) rates were compared based on TUBB3 and hENT1 expression.
Results
The median age was 60 years (range; 38-80 years) and 65% were male patients. The median progression-free survival (PFS) and overall survival (OS) of patients were 6.83 and 12.06 months, respectively. In patients who received the GnP regimen (n=68), a high combined score (TUBB3low/hENT1high) was associated with a higher disease control rate (DCR) (84.2% vs. 39.6%, p=0.001) and longer PFS (8.76 months vs. 3.1 months, p<0.001) compared to those with low score. In the multivariate analysis, a high combined score was an independent predictor of higher DCR (OR: 11.96; 95% CI: 2.61-54.82; p=0.001) and longer PFS (HR: 0.33; 95%CI: 0.18–0.60; p<0.001). However, there was no difference in response rates or PFS based on TUBB3 and hENT1 expression among patients receiving FOLFIRINOX regimen.
Conclusions
Our findings suggest that tumor TUBB3 and hENT1 expression may predict the efficacy of GnP regimen, and low TUBB3 and high hENT1 expression are associated with a higher DCR and longer PFS in patients with advanced PDAC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1701P - Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland
Presenter: Miquel Serra-Burriel
Session: Poster session 22
1702P - Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022
Presenter: Jeroen W. G. Derksen
Session: Poster session 22
1703P - Value of molecular targets and genome-targeted cancer therapies FDA-approved, 2015-2022
Presenter: Ariadna Tibau
Session: Poster session 22
1704P - Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time
Presenter: Molto Consolacion
Session: Poster session 22
1705P - Therapeutic value of first vs supplemental indications of drugs in the US and Europe (2011-2020): Retrospective cohort study
Presenter: Kerstin Vokinger
Session: Poster session 22